Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoantigen DNA vaccine - AstraZeneca/Washington University School of Medicine

Next Previous
Drug Profile

Neoantigen DNA vaccine - AstraZeneca/Washington University School of Medicine

Latest Information Update: 29 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune; Washington University School of Medicine
  • Developer AstraZeneca; Bristol-Myers Squibb; Washington University School of Medicine
  • Class Antigens; Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Small cell lung cancer
  • No development reported Prostate cancer; Triple negative breast cancer

Most Recent Events

  • 14 Dec 2023 Washington University School of Medicine in collaboration with Medimmune terminates a phase-I trial in Triple-negative-breast-cancer in USA due to insufficient funding and unavailability of drugs and equipment (NCT03199040),
  • 25 Jul 2022 Bristol-Myers Squibb and Washington University School of Medicine completes a phase I trial in Prostate cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (IM) (NCT03532217)
  • 03 Jun 2022 Safety and immunogenicity data from a phase I trial in prostate cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top